InMode Newsroom

Jefferies Cuts Inmode to Hold, Cites Macro Pressures

Seeking AlphaJul 23 13:55 ET

InMode Price Target Cut to $19.00/Share From $21.00 by Jefferies

Dow JonesJul 23 06:51 ET

InMode Analyst Ratings

BenzingaJul 23 06:42 ET

InMode's Business Outlook: Maintaining a Hold Rating Amid Market Challenges and Lowered Forecasts

TipRanksJul 23 04:37 ET

Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating

MT NewswiresJul 15 10:45 ET

InMode Analyst Ratings

BenzingaJul 15 08:58 ET

Canaccord Genuity Maintains Hold on InMode, Lowers Price Target to $16

BenzingaJul 12 10:13 ET

InMode Analyst Ratings

BenzingaJul 11 11:14 ET

InMode Analyst Ratings

BenzingaMay 3 06:18 ET

Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating

MT NewswiresApr 12 10:27 ET

InMode Analyst Ratings

BenzingaApr 12 10:01 ET

InMode Analyst Ratings

BenzingaApr 9 11:54 ET

InMode Analyst Ratings

BenzingaFeb 14 14:54 ET

Analysts Offer Insights on Healthcare Companies: MaxCyte (GB:MXCT), Kura Oncology (KURA) and InMode (INMD)

TipRanksJan 23 04:09 ET

InMode Analyst Ratings

BenzingaJan 18 09:07 ET

Barclays Maintains Overweight on InMode, Lowers Price Target to $33

BenzingaJan 4 08:06 ET

InMode Analyst Ratings

BenzingaJan 4 08:04 ET

Analysts Offer Insights on Healthcare Companies: InMode (INMD), Ocular Therapeutix (OCUL) and Adverum Biotechnologies (ADVM)

TipRanksDec 11, 2023 02:20 ET

Canaccord Genuity Reiterates Hold on InMode, Maintains $22 Price Target

BenzingaDec 7, 2023 10:48 ET

InMode Analyst Ratings

BenzingaDec 7, 2023 10:46 ET